Form of Registration Rights Agreement REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 24th, 2020 • Novo Holdings a/S • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of July 16, 2020 by and among Verona Pharma plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of July 16, 2020 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
Form of Lock-Up AgreementLock-Up Agreement • July 16th, 2020 • Novo Holdings a/S • Pharmaceutical preparations • New York
This letter agreement (“Agreement”) is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) among Nkarta, Inc., a Delaware corporation (the “Company”) and Cowen and Company, LLC (“Cowen”), Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of a group of underwriters (collectively, the “Underwriters”), to be named therein, and the other parties thereto (if any), relating to the proposed public offering of shares of the common stock, par value $0.0001 per share (the “Common Stock”) of the Company.
Lock-up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common StockLock-Up Agreement • June 2nd, 2016 • Novo a/S • Pharmaceutical preparations
Lock-up Agreement Merus B.V. Public Offering of Common SharesLock-Up Agreement • May 26th, 2016 • Novo a/S • Pharmaceutical preparations
Edgewise Therapeutics, Inc. Lock-Up AgreementLock-Up Agreement • March 31st, 2021 • Novo Holdings a/S • Pharmaceutical preparations • New York
FORM OF LOCK-UP AGREEMENTLock-Up Agreement • March 31st, 2021 • Novo Holdings a/S • Pharmaceutical preparations • New York
Lock-up Agreement – Novo Holdings A/S Reata Pharmaceuticals, Inc.Lock-Up Agreement • June 26th, 2017 • Novo Holdings a/S • Pharmaceutical preparations
LOCK-UP AGREEMENTLock-Up Agreement • July 29th, 2020 • Novo Holdings a/S • Pharmaceutical preparations
Corvus Pharmaceuticals, Inc.Lock-Up Agreement • March 30th, 2016 • Novo a/S • Pharmaceutical preparations • New York
Lock-up AgreementLock-Up Agreement • April 14th, 2021 • Novo Holdings a/S • Pharmaceutical preparations • New York
Registration Rights Agreement Acknowledgement and Waiver June 22, 2017Registration Rights Agreement • June 26th, 2017 • Novo Holdings a/S • Pharmaceutical preparations
Form of Lock-Up Agreement [Date]Lock-Up Agreement • May 13th, 2015 • Novo a/S • Laboratory analytical instruments
Morgan Stanley & Co. LLC SVB Leerink LLC As Representatives of the several Underwriters listed on Schedule I to the Underwriting Agreement referred to below c/o Morgan Stanley & Co. LLCUnderwriting Agreement • February 11th, 2021 • Novo Holdings a/S • Pharmaceutical preparations • New York
LOCK-UP AGREEMENTLock-Up Agreement • November 10th, 2021 • Novo Holdings a/S • Pharmaceutical preparations • New York
PURCHASE AGREEMENTPurchase Agreement • June 26th, 2017 • Novo Holdings a/S • Pharmaceutical preparations • New York
This Purchase Agreement, dated as of June 22, 2017, is by and among the funds listed on Schedule I hereto (each a “Purchaser” and, collectively, the “Purchasers”), Reata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Novo A/S, a Danish limited liability company in the process of changing its name to “Novo Holdings A/S” (the “Seller”). The Purchasers and the Seller are sometimes referred to collectively herein as the “Parties,” which term shall also refer to the Company for the purposes of Section 3.1, or an amendment of Section 3.1, only.
Morgan Stanley & Co. LLC BofA Securities, Inc. As representatives of the several underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J.P. Morgan Securities LLCUnderwriting Agreement • June 25th, 2021 • Novo Holdings a/S • Pharmaceutical preparations • New York
BofA Securities, Inc. Jefferies LLC BMO Capital Markets Corp. as Representatives of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Jefferies...Underwriting Agreement • August 13th, 2020 • Novo Holdings a/S • Biological products, (no disgnostic substances)
FORM OF LOCK-UP AGREEMENTLock-Up Agreement • October 22nd, 2020 • Novo Holdings a/S • Biological products, (no disgnostic substances) • New York
Form of lock-up from directors, officers or other stockholders October , 2020Lock-Up Agreement • November 5th, 2020 • Novo Holdings a/S • Pharmaceutical preparations
Form of Lock-Up AgreementLock-Up Agreement • May 13th, 2015 • Novo a/S • Pharmaceutical preparations
Flexion Therapeutics, Inc. Public Offering of Common StockUnderwriting Agreement • February 26th, 2014 • Novo a/S • Pharmaceutical preparations
Lock-Up AgreementLock-Up Agreement • October 16th, 2020 • Novo Holdings a/S • Pharmaceutical preparations • New York
This letter agreement (“Agreement”) is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) between Spruce Biosciences, Inc., a Delaware corporation (the “Company”) and Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC, and RBC Capital Markets, LLC, as representatives (the “Representatives”) of a group of underwriters (collectively, the “Underwriters”), to be named therein, and the other parties thereto (if any), relating to the proposed public offering (the “Offering”) of shares of the common stock, par value $0.0001 per share (the “Common Stock”) of the Company.
